Aperture

Genetic medicine for neurodegeneration

Human 3 criteria:

AI enabled

Step change

Aperture is developing ASO therapeutics for neurodegenerative diseases by leveraging insights from the genetic profiles of naturally disease resilient individuals.

Under the radar for now - more info soon.

2024

XEIA invests

The latest from 

Aperture

coming soon . . .

Want more from XEIA?

Stay up to date on Human 3 - the new epoch of health, wellbeing and performance

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! You've been added to our mailing list.
Oops! Something went wrong while submitting the form.
X-disciplinary Exploration, Investment & Acceleration

© 2025 XEIA Venture Partners, LLC